<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="Letter to the Editor" dtd-version="1.0"><front><journal-meta><journal-id journal-id-type="pmc">iarjms</journal-id><journal-id journal-id-type="pubmed">IARJMS</journal-id><journal-id journal-id-type="publisher">IARJMS</journal-id><issn>2708-3594</issn></journal-meta><article-meta><article-id pub-id-type="doi">https://doi.org/10.47310/iarjms.2021.v02i01.047</article-id><title-group><article-title>Cardiac Compromise in COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><given-names>Josef</given-names><surname>Finsterer</surname></name></contrib><xref ref-type="aff" rid="aff-a" /></contrib-group><aff-id id="aff-a">Klinik Landstrasse, Messerli Institute, Postfach 20, Vienna, Austria</aff-id><abstract>Cardiac complications in SARS-CoV-2 infected patients not only include myocardial injury, myocarditis, Takotsubo cardiomyopathy (TTS), coagulation abnormalities. heart failure, cardiac arrest, arrhythmias, acute myocardial infarction or cardiogenic shock but is more variegated. Additionally considered should be endocarditis due to superinfection, viral or bacterial pericarditis, aortic dissection, pulmonary embolism from the right atrium, ventricle or outflow tract and cardiac autonomic denervation. Cardiac damage due to side effects from the anti-COVID medication should not be neglected.&amp;nbsp;</abstract></article-meta></front><body /><back /></article>